The latest update is out from Medicus Pharma Ltd ( (MDCX) ).
Medicus Pharma Ltd has submitted a Phase 2 clinical design to the UAE Department of Health for a study aimed at non-invasively treating basal cell carcinoma of the skin. The study will involve 36 participants across four clinical sites in the UAE and will evaluate the efficacy of two dose levels of D-MNA. The company’s previous Phase 1 study demonstrated safety and tolerability, and the ongoing Phase 2 study in the United States is progressing well, with plans to seek FDA fast-track approval.
More about Medicus Pharma Ltd
Medicus Pharma Ltd is a pharmaceutical company operating in the healthcare industry, focusing on developing non-invasive treatments for skin conditions such as basal cell carcinoma (BCC). The company is involved in clinical research and development, with a market focus on innovative dermatological therapies.
Average Trading Volume: 1,347
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: C$67.84M
Learn more about MDCX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com